JP2007522137A - ざ瘡を治療するための光線力学療法 - Google Patents
ざ瘡を治療するための光線力学療法 Download PDFInfo
- Publication number
- JP2007522137A JP2007522137A JP2006551694A JP2006551694A JP2007522137A JP 2007522137 A JP2007522137 A JP 2007522137A JP 2006551694 A JP2006551694 A JP 2006551694A JP 2006551694 A JP2006551694 A JP 2006551694A JP 2007522137 A JP2007522137 A JP 2007522137A
- Authority
- JP
- Japan
- Prior art keywords
- photosensitizer
- acne
- skin
- topical
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010000496 acne Diseases 0.000 title claims abstract description 61
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 58
- 238000002428 photodynamic therapy Methods 0.000 title claims abstract description 33
- 239000003504 photosensitizing agent Substances 0.000 claims abstract description 90
- 239000000203 mixture Substances 0.000 claims abstract description 64
- 150000004032 porphyrins Chemical class 0.000 claims abstract description 37
- 238000000034 method Methods 0.000 claims abstract description 32
- LHXFPSQJODNWEW-DVNHMXKTSA-N CCCOC(CCC1=C(/C=C2\N=C(/C=C(/C(C)(C3C(OC)=O)C4=CC=C3C(OC)=O)\N/C\4=C\C(C(C)=C3C=C)=N/C\3=C3)C(C)=C\2CCC(OCCO)=O)NC/3=C1C)=O Chemical compound CCCOC(CCC1=C(/C=C2\N=C(/C=C(/C(C)(C3C(OC)=O)C4=CC=C3C(OC)=O)\N/C\4=C\C(C(C)=C3C=C)=N/C\3=C3)C(C)=C\2CCC(OCCO)=O)NC/3=C1C)=O LHXFPSQJODNWEW-DVNHMXKTSA-N 0.000 claims abstract description 11
- 229950002747 lemuteporfin Drugs 0.000 claims abstract description 10
- 239000003961 penetration enhancing agent Substances 0.000 claims abstract description 8
- 238000011282 treatment Methods 0.000 claims description 26
- 239000002904 solvent Substances 0.000 claims description 18
- 230000000699 topical effect Effects 0.000 claims description 17
- 230000003902 lesion Effects 0.000 claims description 16
- 208000024891 symptom Diseases 0.000 claims description 13
- 230000001747 exhibiting effect Effects 0.000 claims description 11
- 230000003213 activating effect Effects 0.000 claims description 9
- 238000005406 washing Methods 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 5
- 229940088710 antibiotic agent Drugs 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 239000004615 ingredient Substances 0.000 claims description 5
- ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N verteporfin Chemical compound C=1C([C@@]2([C@H](C(=O)OC)C(=CC=C22)C(=O)OC)C)=NC2=CC(C(=C2C=C)C)=NC2=CC(C(=C2CCC(O)=O)C)=NC2=CC2=NC=1C(C)=C2CCC(=O)OC ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N 0.000 claims description 5
- 229960003895 verteporfin Drugs 0.000 claims description 5
- 238000001126 phototherapy Methods 0.000 claims description 4
- 150000004492 retinoid derivatives Chemical class 0.000 claims description 4
- 230000002280 anti-androgenic effect Effects 0.000 claims description 3
- 239000000051 antiandrogen Substances 0.000 claims description 3
- 239000003599 detergent Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000004744 fabric Substances 0.000 claims description 3
- 238000002647 laser therapy Methods 0.000 claims description 3
- 239000000344 soap Substances 0.000 claims description 3
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 claims description 2
- 229940127234 oral contraceptive Drugs 0.000 claims description 2
- 239000003539 oral contraceptive agent Substances 0.000 claims description 2
- 239000002453 shampoo Substances 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract description 18
- 239000002202 Polyethylene glycol Substances 0.000 abstract description 14
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 abstract description 12
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 abstract description 6
- 229940055577 oleyl alcohol Drugs 0.000 abstract description 6
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 abstract description 6
- 230000002209 hydrophobic effect Effects 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 37
- 230000004913 activation Effects 0.000 description 23
- 210000001519 tissue Anatomy 0.000 description 21
- 238000009472 formulation Methods 0.000 description 19
- 229960003511 macrogol Drugs 0.000 description 13
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 11
- -1 porphyrin compounds Chemical class 0.000 description 11
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 229960002749 aminolevulinic acid Drugs 0.000 description 8
- 210000004209 hair Anatomy 0.000 description 8
- 230000035515 penetration Effects 0.000 description 8
- 238000012384 transportation and delivery Methods 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000003623 enhancer Substances 0.000 description 6
- 210000001732 sebaceous gland Anatomy 0.000 description 6
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 125000005456 glyceride group Chemical group 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- 238000005698 Diels-Alder reaction Methods 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 150000002191 fatty alcohols Chemical class 0.000 description 3
- 229930182478 glucoside Natural products 0.000 description 3
- 150000008131 glucosides Chemical class 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 229960005280 isotretinoin Drugs 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 150000004033 porphyrin derivatives Chemical class 0.000 description 3
- CCXUFFTYEJRDBY-UHFFFAOYSA-N propylene glycol mono- and diesters of fats and fatty acids Chemical class CCCCCCCCCCCCCCC(=O)OC(C)COC(=O)CCCCCCCCCCCCC CCXUFFTYEJRDBY-UHFFFAOYSA-N 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- RFIMISVNSAUMBU-UHFFFAOYSA-N 2-(hydroxymethyl)-2-(prop-2-enoxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)COCC=C RFIMISVNSAUMBU-UHFFFAOYSA-N 0.000 description 2
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 2
- BHIZVZJETFVJMJ-UHFFFAOYSA-N 2-hydroxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)O BHIZVZJETFVJMJ-UHFFFAOYSA-N 0.000 description 2
- GHHURQMJLARIDK-UHFFFAOYSA-N 2-hydroxypropyl octanoate Chemical compound CCCCCCCC(=O)OCC(C)O GHHURQMJLARIDK-UHFFFAOYSA-N 0.000 description 2
- QPILHXCDZYWYLQ-UHFFFAOYSA-N 2-nonyl-1,3-dioxolane Chemical compound CCCCCCCCCC1OCCO1 QPILHXCDZYWYLQ-UHFFFAOYSA-N 0.000 description 2
- MHIITNFQDPFSES-UHFFFAOYSA-N 25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1(25),2,4,6,8(27),9,11,13,15,17,19,21,23-tridecaene Chemical class N1C(C=C2C3=CC=CC=C3C(C=C3NC(=C4)C=C3)=N2)=CC=C1C=C1C=CC4=N1 MHIITNFQDPFSES-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- LYPFDBRUNKHDGX-SOGSVHMOSA-N N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 Chemical compound N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 LYPFDBRUNKHDGX-SOGSVHMOSA-N 0.000 description 2
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 2
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- DSJXIQQMORJERS-AGGZHOMASA-M bacteriochlorophyll a Chemical class C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC([C@H](CC)[C@H]3C)=[N+]4C3=CC3=C(C(C)=O)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 DSJXIQQMORJERS-AGGZHOMASA-M 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000005670 electromagnetic radiation Effects 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 150000002194 fatty esters Chemical class 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229940118199 levulan Drugs 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- YUUAYBAIHCDHHD-UHFFFAOYSA-N methyl 5-aminolevulinate Chemical compound COC(=O)CCC(=O)CN YUUAYBAIHCDHHD-UHFFFAOYSA-N 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 108010013121 palladium-bacteriopheophorbide Proteins 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068965 polysorbates Drugs 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 229940026235 propylene glycol monolaurate Drugs 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 230000037387 scars Effects 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960002197 temoporfin Drugs 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 239000004034 viscosity adjusting agent Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- ILBBNQMSDGAAPF-UHFFFAOYSA-N 1-(6-hydroxy-6-methylcyclohexa-2,4-dien-1-yl)propan-1-one Chemical compound CCC(=O)C1C=CC=CC1(C)O ILBBNQMSDGAAPF-UHFFFAOYSA-N 0.000 description 1
- HMSMOZAIMDNRBW-UHFFFAOYSA-N 100572-96-1 Chemical compound C1=CC2=NC1=CC=C(N1)C=CC1=C(N1)C=CC1=CC=C1C=CC2=N1 HMSMOZAIMDNRBW-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- PWVUXRBUUYZMKM-UHFFFAOYSA-N 2-(2-hydroxyethoxy)ethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOCCO PWVUXRBUUYZMKM-UHFFFAOYSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 108010003118 Bacteriochlorophylls Proteins 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- PLVAJLBZYYGQNL-UHFFFAOYSA-N C12CC=C(N1)C=C1C=CC(=N1)C=C1C=CC(N1)=CC=1C3=C(C(N=1)=C2)C=CC=C3 Chemical compound C12CC=C(N1)C=C1C=CC(=N1)C=C1C=CC(N1)=CC=1C3=C(C(N=1)=C2)C=CC=C3 PLVAJLBZYYGQNL-UHFFFAOYSA-N 0.000 description 1
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical group CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 1
- JUDGRMABQJKRPW-XIADSQHASA-N CCC1=C(/C=C2\N=C(/C(\CC3=O)=C(/[C@@H](CCC(O)=O)[C@@H]4C)\N/C\4=C\C(C(C)=C4C=C)=N/C\4=C4)C3=C\2C)NC/4=C1C Chemical compound CCC1=C(/C=C2\N=C(/C(\CC3=O)=C(/[C@@H](CCC(O)=O)[C@@H]4C)\N/C\4=C\C(C(C)=C4C=C)=N/C\4=C4)C3=C\2C)NC/4=C1C JUDGRMABQJKRPW-XIADSQHASA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000851593 Homo sapiens Separin Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 229910052765 Lutetium Inorganic materials 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 229920002507 Poloxamer 124 Polymers 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 108050001408 Profilin Chemical class 0.000 description 1
- 102000011195 Profilin Human genes 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 102100036750 Separin Human genes 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- UWHCKJMYHZGTIT-UHFFFAOYSA-N Tetraethylene glycol, Natural products OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 1
- 150000000475 acetylene derivatives Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- BHPNXACHQYJJJS-UHFFFAOYSA-N bacteriochlorin Chemical compound N1C(C=C2N=C(C=C3NC(=C4)C=C3)CC2)=CC=C1C=C1CCC4=N1 BHPNXACHQYJJJS-UHFFFAOYSA-N 0.000 description 1
- 150000004036 bacteriochlorins Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003007 chemical teratogen Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical class OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229940100242 glycol stearate Drugs 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 1
- LZYXPFZBAZTOCH-UHFFFAOYSA-N hexyl 5-amino-4-oxopentanoate;hydron;chloride Chemical compound Cl.CCCCCCOC(=O)CCC(=O)CN LZYXPFZBAZTOCH-UHFFFAOYSA-N 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- FWBFDXIBOYYUPH-DBLYXWCISA-N isobacteriochlorin Chemical compound C1C\C2=C\C3=N\C(\C=C3)=C/C3=CC=C(N3)\C=C3\CCC(\C=C1/N2)=N3 FWBFDXIBOYYUPH-DBLYXWCISA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 229960003639 laurocapram Drugs 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 125000002669 linoleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- OHSVLFRHMCKCQY-UHFFFAOYSA-N lutetium atom Chemical compound [Lu] OHSVLFRHMCKCQY-UHFFFAOYSA-N 0.000 description 1
- 150000002678 macrocyclic compounds Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- LKKPNUDVOYAOBB-UHFFFAOYSA-N naphthalocyanine Chemical compound N1C(N=C2C3=CC4=CC=CC=C4C=C3C(N=C3C4=CC5=CC=CC=C5C=C4C(=N4)N3)=N2)=C(C=C2C(C=CC=C2)=C2)C2=C1N=C1C2=CC3=CC=CC=C3C=C2C4=N1 LKKPNUDVOYAOBB-UHFFFAOYSA-N 0.000 description 1
- GLZWNFNQMJAZGY-UHFFFAOYSA-N octaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCO GLZWNFNQMJAZGY-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000003209 petroleum derivative Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000002165 photosensitisation Effects 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 1
- 229940093448 poloxamer 124 Drugs 0.000 description 1
- 229920000059 polyethylene glycol stearate Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229930188006 polyphyllin Natural products 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 229940093625 propylene glycol monostearate Drugs 0.000 description 1
- BBNQQADTFFCFGB-UHFFFAOYSA-N purpurin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC(O)=C3C(=O)C2=C1 BBNQQADTFFCFGB-UHFFFAOYSA-N 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- XXUZFRDUEGQHOV-UHFFFAOYSA-J strontium ranelate Chemical compound [Sr+2].[Sr+2].[O-]C(=O)CN(CC([O-])=O)C=1SC(C([O-])=O)=C(CC([O-])=O)C=1C#N XXUZFRDUEGQHOV-UHFFFAOYSA-J 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960000565 tazarotene Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Radiation-Therapy Devices (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
(i)尋常性ざ瘡に冒されている組織に、光線感作物質を送達するステップと、
(ii)この組織を、光線感作物質を活性化することが可能な波長のエネルギーに曝露するステップと
を含む。
(i)ざ瘡の症状を示す皮膚組織に、緑色ポルフィリンと溶解剤とを含む組成物を外用施用するステップと、
(ii)光線感作物質を活性化することが可能な波長のエネルギーに、この組織を曝露するステップと
を含む。
(i)ざ瘡の症状を示す皮膚組織に、光線感作物質を含む組成物を外用施用するステップと、
(ii)この皮膚から、過剰な組成物を除去するステップと、
(iii)光線感作物質を活性化することが可能な波長のエネルギーに、この組織を曝露するステップと
を含む。
(i)ざ瘡の症状を示す皮膚組織に、緑色ポルフィリンと溶解剤とを含む組成物を外用施用するステップと、
(ii)光線感作物質を活性化することが可能な波長のエネルギーに、この組織を曝露するステップと
を含み、この治療を、ざ瘡病変の総数が10%以上減少するまで繰り返す。病変の総数は、15%、20%、25%、30%、35%、40%、45%、50%、60%、70%、80%、90%以上減少することが好ましい。病変の総数は、治療開始前に、複数の試験領域のうち1つを予め定義することによって評価することができる。試験領域内で、病変のカウント(非炎症性、炎症性、及び合計)を行う。試験領域内での病変のサイズも記録する。試験領域の写真も撮る。代表例とするため、患者1人当たり、いくつかの試験領域を選択するが、これらは、その患者の病変の解剖学的分布に応じて変わり得る。試験領域について、光線力学療法の終了から1日後、1週間後、2週間後、及び1カ月後に再評価する。次いで病変カウント数の減少を計算する。好ましい光線力学的治療法、組成物、及びパラメータについて、以下により詳細に記載する。
(i)ざ瘡の症状を示す皮膚を、光線力学的に治療するステップと、
(ii)外用レチノイド、経口レチノイド、抗生物質(特に外用)、経口避妊薬、外用抗アンドロゲン、青色光療法、レーザ療法、又はこれらの組合せで、同じ患者を治療するステップと
を含む。
(i)ざ瘡の症状を示す皮膚組織に、緑色ポルフィリンと溶解剤とを含む組成物を外用施用するステップと、
(ii)光線感作物質を活性化することが可能な波長のエネルギーに、この組織を曝露するステップと
を含み、
活性化エネルギーは、発光ダイオードによって少なくとも部分的に供給されるものである。LEDは、治療すべき皮膚の輪郭をいくらか辿るように配列することが好ましい。好ましい配置構成は、適切に位置決めすることができるように移動可能な、多数のフラットパネルのLEDである。上述のように、PDTは、付加的な効力上の利益が得られるように、青色光線療法と併用することができる。したがって、本発明のこの態様の一実施形態は、赤色光(例えば600〜750nm)及び青色光(例えば390〜450nm)の両方を供給するLEDデバイスによって送達される、活性化エネルギーを含む。好ましい実施形態は、約420nm及び約690nmの光を供給する。好ましい光線力学的治療法、組成物、及びパラメータについて、以下により詳細に記載する。
(i)ざ瘡の症状を示す皮膚組織に、緑色ポルフィリンを含む組成物を外用施用するステップと、
(ii)光線感作物質を活性化することが可能な波長のエネルギーに、この組織を曝露するステップと、
(iii)別の非緑色ポルフィリン光線感作物質で、この組織を光線力学的に治療するステップと
を含む。
本明細書の光線感作物質は、標的組織に外用送達することが好ましい。外用送達によって、光線感作物質の全身送達に関連した光感受性問題のいくつかが回避される。光線感作物質を外用施用する場合、この物質は、ざ瘡病変のみに施用することができ、又は好ましくは、ざ瘡病変とその周囲の冒されていない組織に施用することができる。
a)ざ瘡に冒された皮膚に、光線感作物質を外用投与するステップ。組成物は、光線感作物質及び皮膚浸透増強剤を含むことが好ましい。好ましい光線感作物質は、ベルテポルフィン、レムテポルフィン、及びこれらの組合せから選択される。
b)LEDを介して活性化エネルギーを投与するステップ。活性化エネルギーは、施用してから60分以内に投与することが好ましい。好ましい線量は、15から200J/cm2の間である。より好ましい線量には、20、40、80、又は120J/cm2が含まれる。
Claims (19)
- (i)ざ瘡の症状を示す皮膚組織に、緑色ポルフィリン光線感作物質と溶解剤とを含む組成物を外用施用するステップと、
(ii)前記光線感作物質を活性化することが可能な波長のエネルギーに、前記組織を曝露するステップと
によって、尋常性ざ瘡を治療する方法。 - 光線感作物質が、ベルテポルフィン、レムテポルフィン、及びこれらの組合せから選択される、請求項1に記載の方法。
- 組成物が、20℃で約50cpsから約50000cpsの粘度を有する、請求項1又は2に記載の方法。
- (i)ざ瘡の症状を示す皮膚組織に、光線感作物質を含む組成物を外用施用するステップと、
(ii)前記皮膚から過剰な組成物を除去するステップと、
(iii)前記光線感作物質を活性化することが可能な波長のエネルギーに、前記組織を曝露するステップと
によって、尋常性ざ瘡を治療する方法。 - 光線感作物質が緑色ポルフィリンから選択される、請求項4に記載の方法。
- 光線感作物質が、ベルテポルフィン、レムテポルフィン、及びこれらの組合せから選択される、請求項4に記載の方法。
- 乾燥した布での拭き取り、湿ったタオレットでの拭き取り、アルコールでの洗浄、石鹸成分を含まない清浄剤での洗浄、刺激性の少ないシャンプーでの洗浄、及びこれらの組合せによって過剰な組成物を除去する、請求項4、5、又は6に記載の方法。
- (i)ざ瘡の症状を示す皮膚組織に、緑色ポルフィリンと溶解剤とを含む組成物を外用施用するステップと、
(ii)前記光線感作物質を活性化することが可能な波長のエネルギーに、前記組織を曝露するステップと
によって、尋常性ざ瘡を治療する方法であって、前記治療を、ざ瘡の病変の総数が30%以上減少するまで繰り返す方法。 - (i)ざ瘡の症状を示す皮膚を光線力学的に治療するステップと、
(ii)外用レチノイド、経口レチノイド、全身性抗生物質、外用又は局所抗生物質、経口避妊薬、外用抗アンドロゲン、青色光療法、レーザ療法、又はこれらの組合せで、同じ患者を治療するステップと
によって、尋常性ざ瘡を治療する方法。 - 光線力学療法が、請求項1から7のいずれか記載の方法によって実施される、請求項9に記載の方法。
- 非光線力学療法が、外用レチノイド、経口レチノイド、外用抗生物質、外用抗アンドロゲン、又はこれらの組合せから選択される、請求項9又は10に記載の方法。
- 非光線力学療法が外用レチノイドから選択される、請求項9又は10に記載の方法。
- (i)ざ瘡の症状を示す皮膚組織に、緑色ポルフィリンと皮膚浸透増強剤とを含む組成物を、外用施用するステップと、
(ii)赤色光を発するLED及び青色光を発するLEDを含む発光ダイオードデバイスによって供給される光で、前記組織を露光するステップと
によって、尋常性ざ瘡を治療する方法。 - 赤色発光LEDが、600〜750nmの範囲内で発光し、青色発光LEDが、390〜450nmの範囲内で発光する、請求項13に記載の方法。
- 尋常性ざ瘡を治療する外用薬剤を調製するための、緑色ポルフィリン光線感作物質及び溶解剤の使用であって、前記光線感作物質が、選択された波長のエネルギーによって活性化することが可能である使用。
- 光線感作物質が、ベルテポルフィン、レムテポルフィン、及びこれらの組合せから選択される、請求項15に記載の光線感作物質の使用。
- 薬剤が、20℃で約50cpsから約50000cpsの粘度を有する、請求項15又は16に記載の光線感作物質の使用。
- 光線感作物質が緑色ポルフィリンから選択される、請求項15に記載の光線感作物質の使用。
- 波長が、600から750nm又は390〜450nmの範囲内である、請求項15から18のいずれか一項に記載の光線感作物質の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002457214A CA2457214A1 (en) | 2004-02-06 | 2004-02-06 | Photodynamic therapy for the treatment of acne |
CA002470403A CA2470403A1 (en) | 2004-02-06 | 2004-06-09 | Photodynamic therapy for the treatment of hyperactive sebaceous gland disorders |
PCT/CA2005/000141 WO2005074987A1 (en) | 2004-02-06 | 2005-02-04 | Photodynamic therapy for the treatment of acne |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007522137A true JP2007522137A (ja) | 2007-08-09 |
JP2007522137A5 JP2007522137A5 (ja) | 2008-03-27 |
Family
ID=34839264
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006551694A Pending JP2007522137A (ja) | 2004-02-06 | 2005-02-04 | ざ瘡を治療するための光線力学療法 |
Country Status (7)
Country | Link |
---|---|
US (2) | US20100056982A1 (ja) |
EP (3) | EP2494989A1 (ja) |
JP (1) | JP2007522137A (ja) |
AU (1) | AU2005209955A1 (ja) |
BR (1) | BRPI0507406A (ja) |
CA (3) | CA2457214A1 (ja) |
WO (1) | WO2005074987A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010071230A1 (ja) | 2008-12-17 | 2010-06-24 | 学校法人慶應義塾 | 細胞特異的能動集積性を有する光線力学療法剤 |
JP2011513213A (ja) * | 2008-02-25 | 2011-04-28 | ロレアル | 皮膚および/または髪の外観を改善するための、光線とリパーゼにより生物学的に変換可能な化合物との組合せ |
JP2013532035A (ja) * | 2010-07-09 | 2013-08-15 | フォトキュア エイエスエイ | 光力学的治療または光力学的診断で使用する乾燥組成物および当該乾燥組成物を含む装置 |
JP2016525540A (ja) * | 2013-07-23 | 2016-08-25 | ドンスン ファーム カンパニー リミテッド | にきび治療、予防または改善に有効なクロリンe6 |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008501727A (ja) * | 2004-06-09 | 2008-01-24 | キュー エル ティー インク. | 外用塗布した疎水性緑色ポルフィリンを用いた機能亢進性皮脂腺障害を治療するための光線力学的療法 |
AU2011253786B2 (en) * | 2004-06-09 | 2014-10-09 | Valeant Pharmaceuticals International, Inc. | Photodynamic therapy for the treatment of hyperactive sebaceous gland disorders using topically applied hydrophobic green porphyrins |
US20090131499A1 (en) * | 2007-11-15 | 2009-05-21 | Ceramoptec Industries Inc. | Photodynamic therapy for skin related problems |
WO2009093144A2 (en) * | 2008-01-25 | 2009-07-30 | Qlt, Inc.Lau | Photodynamic therapy of sebaceous gland disorders |
US8815931B2 (en) * | 2009-04-28 | 2014-08-26 | Biolitec Pharma Marketing Ltd | Oral formulations for tetrapyrrole derivatives |
US20120136055A1 (en) * | 2009-06-11 | 2012-05-31 | Photocure Asa | Semi-solid compositions and pharmaceutical products |
MX2012000435A (es) | 2009-07-08 | 2012-06-01 | Dermira Canada Inc | Analogos de acido 5-(tetradeciloxi)-2-furancarboxilico (tofa) utiles en el tratamiento de trastornos o afecciones dermatologicas. |
EP2663285A2 (en) | 2011-01-13 | 2013-11-20 | Qlt Inc. | Pharmaceutical compositions for topical delivery of photosensitizers and uses thereof |
US9687669B2 (en) | 2011-11-09 | 2017-06-27 | John Stephan | Wearable light therapy apparatus |
US20130281913A1 (en) | 2012-04-20 | 2013-10-24 | Klox Technologies Inc. | Biophotonic compositions and methods for providing biophotonic treatment |
WO2014011875A1 (en) | 2012-07-11 | 2014-01-16 | Dermira, Inc. | Pharmaceutical compositions for topical delivery of photosensitizers and uses thereof |
JP2016511672A (ja) * | 2013-03-01 | 2016-04-21 | クロックス テクノロジーズ インコーポレイテッドKlox Technologies Inc. | 光線療法装置、方法および使用 |
KR20150004092A (ko) * | 2013-07-02 | 2015-01-12 | 제너럴바이오(주) | 칼란코에 추출물이 포함된 항산화 액상 조성물 |
CA2916337C (en) | 2013-07-03 | 2022-03-22 | Klox Technologies Inc. | Biophotonic compositions comprising a chromophore and a gelling agent for treating wounds |
EP3799868A1 (en) * | 2013-12-20 | 2021-04-07 | Galderma Research & Development | Pulse photodynamic treatment of photodamaged skin |
AR099941A1 (es) | 2014-04-01 | 2016-08-31 | Klox Tech Inc | Composiciones para relleno de tejido y métodos de uso |
US9950147B2 (en) * | 2014-09-12 | 2018-04-24 | Je Matadi, Inc. | Apparatus and method for administering a skin care composition |
CA2984963A1 (en) * | 2015-05-12 | 2016-11-17 | Klox Technologies Inc. | Devices and methods for phototherapy |
US20190083809A1 (en) | 2016-07-27 | 2019-03-21 | Z2020, Llc | Componentry and devices for light therapy delivery and methods related thereto |
CN112451862B (zh) * | 2020-11-24 | 2023-03-28 | 深圳罗兹曼国际转化医学研究院 | 光动力治疗系统及其控制方法 |
WO2023059180A1 (en) * | 2021-10-06 | 2023-04-13 | Tunku Abdul Rahman University Of Management And Technology (Tar Umt) | Treating skin diseases using a photodynamic therapy (pdt) and a topical agent photosensitizer formulation |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003039597A1 (en) * | 2001-11-09 | 2003-05-15 | Qlt Inc. | Compositions comprising a photosensitizer and a skin-penetration enhancer and their use in photodynamic treatment |
WO2003086460A2 (en) * | 2002-04-05 | 2003-10-23 | Candela Corporation | High fluence rate activation of photosensitizers for dermatological applications |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4861764A (en) | 1986-11-17 | 1989-08-29 | Macro Chem. Corp. | Percutaneous absorption enhancers, compositions containing same and method of use |
US5095030A (en) | 1987-01-20 | 1992-03-10 | University Of British Columbia | Wavelength-specific cytotoxic agents |
US5283255A (en) * | 1987-01-20 | 1994-02-01 | The University Of British Columbia | Wavelength-specific cytotoxic agents |
US4920143A (en) * | 1987-04-23 | 1990-04-24 | University Of British Columbia | Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents |
US5171749A (en) * | 1987-01-20 | 1992-12-15 | University Of British Columbia | Wavelength-specific cytotoxic agents |
US4883790A (en) | 1987-01-20 | 1989-11-28 | University Of British Columbia | Wavelength-specific cytotoxic agents |
GB8805849D0 (en) | 1988-03-11 | 1988-04-13 | Efamol Holdings | Porphyrins & cancer treatment |
US5955490A (en) * | 1989-07-28 | 1999-09-21 | Queen's University At Kingston | Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins |
US6492420B2 (en) * | 1995-03-10 | 2002-12-10 | Photocure As | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy |
IL116126A0 (en) | 1995-11-24 | 1996-01-31 | Yeda Res & Dev | Process for the preparation of bacteriochlorophyllis some novel compounds of this type and pharmaceutical compositions comprising them |
US5880145A (en) * | 1997-05-07 | 1999-03-09 | The University Of British Columbia | Class of benzoporphyrin derivative photoactive compounds |
PT983272E (pt) | 1997-05-07 | 2004-03-31 | Univ British Columbia | Nova classe de compostos fotoactivos derivados de benzoporfirina |
KR100397131B1 (ko) | 1997-05-07 | 2003-09-13 | 유니버시티 오브 브리티시 콜롬비아 | 광활성제로서 모노하이드로벤조포르피린 유도체의 에틸렌글리콜 에스테르 |
US6004821A (en) | 1998-03-07 | 1999-12-21 | Levine; Robert A. | Method and apparatus for performing chemical, qualitative, quantitative, and semi-quantitative analyses of a urine sample |
JP2002526128A (ja) | 1998-07-09 | 2002-08-20 | キュアライト・リミテッド | にきび及び脂漏症のために有効な高エネルギ光力学治療装置及び方法 |
EP1100490B1 (en) * | 1998-07-28 | 2006-12-13 | Susan Bershad | Short contact treatment of acne and photoaging with topical retinoids |
US6887260B1 (en) * | 1998-11-30 | 2005-05-03 | Light Bioscience, Llc | Method and apparatus for acne treatment |
US6183773B1 (en) * | 1999-01-04 | 2001-02-06 | The General Hospital Corporation | Targeting of sebaceous follicles as a treatment of sebaceous gland disorders |
IL133253A0 (en) | 1999-12-01 | 2001-04-30 | Yeda Res & Dev | Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them |
GB0005855D0 (en) | 2000-03-10 | 2000-05-03 | Scotia Holdings Plc | Compounds for pdt |
GB2360459B (en) | 2000-03-23 | 2002-08-07 | Photo Therapeutics Ltd | Therapeutic light source and method |
GB2361430A (en) * | 2000-04-17 | 2001-10-24 | Photo Therapeutics Ltd | Therapeutic discharge lamps |
GB0018528D0 (en) | 2000-07-27 | 2000-09-13 | Photocure Asa | Compounds |
ATE463237T1 (de) | 2000-08-16 | 2010-04-15 | Gen Hospital Corp | Topische aminolevulinsäure-photodynamische therapie für akne vulgaris |
GB2368020A (en) * | 2000-10-18 | 2002-04-24 | Icn Photonics Ltd | Treatment of acne vulgaris skin condition by irradiation with light of specific wavelengths to target specific chromophores & stimulate collagen production |
US6984395B2 (en) * | 2001-04-11 | 2006-01-10 | Qlt, Inc. | Drug delivery system for hydrophobic drugs |
US7018396B2 (en) * | 2001-08-07 | 2006-03-28 | New England Medical Center Hospitals, Inc. | Method of treating acne |
US20040228822A1 (en) * | 2003-05-16 | 2004-11-18 | Khaiat Alain V. | Topical treatment of skin conditions |
-
2004
- 2004-02-06 CA CA002457214A patent/CA2457214A1/en not_active Abandoned
- 2004-06-09 CA CA002470403A patent/CA2470403A1/en not_active Abandoned
-
2005
- 2005-02-04 CA CA2554591A patent/CA2554591C/en not_active Expired - Fee Related
- 2005-02-04 WO PCT/CA2005/000141 patent/WO2005074987A1/en active Application Filing
- 2005-02-04 EP EP12170201A patent/EP2494989A1/en not_active Withdrawn
- 2005-02-04 JP JP2006551694A patent/JP2007522137A/ja active Pending
- 2005-02-04 US US10/588,571 patent/US20100056982A1/en not_active Abandoned
- 2005-02-04 AU AU2005209955A patent/AU2005209955A1/en not_active Abandoned
- 2005-02-04 EP EP13165960.9A patent/EP2659909A3/en not_active Withdrawn
- 2005-02-04 BR BRPI0507406-1A patent/BRPI0507406A/pt not_active IP Right Cessation
- 2005-02-04 EP EP05714422A patent/EP1720576A4/en not_active Withdrawn
- 2005-02-08 US US10/588,419 patent/US20080096857A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003039597A1 (en) * | 2001-11-09 | 2003-05-15 | Qlt Inc. | Compositions comprising a photosensitizer and a skin-penetration enhancer and their use in photodynamic treatment |
WO2003086460A2 (en) * | 2002-04-05 | 2003-10-23 | Candela Corporation | High fluence rate activation of photosensitizers for dermatological applications |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011513213A (ja) * | 2008-02-25 | 2011-04-28 | ロレアル | 皮膚および/または髪の外観を改善するための、光線とリパーゼにより生物学的に変換可能な化合物との組合せ |
WO2010071230A1 (ja) | 2008-12-17 | 2010-06-24 | 学校法人慶應義塾 | 細胞特異的能動集積性を有する光線力学療法剤 |
JP2013532035A (ja) * | 2010-07-09 | 2013-08-15 | フォトキュア エイエスエイ | 光力学的治療または光力学的診断で使用する乾燥組成物および当該乾燥組成物を含む装置 |
JP2016525540A (ja) * | 2013-07-23 | 2016-08-25 | ドンスン ファーム カンパニー リミテッド | にきび治療、予防または改善に有効なクロリンe6 |
Also Published As
Publication number | Publication date |
---|---|
AU2005209955A1 (en) | 2005-08-18 |
US20080096857A1 (en) | 2008-04-24 |
EP1720576A1 (en) | 2006-11-15 |
BRPI0507406A (pt) | 2007-06-26 |
WO2005074987A1 (en) | 2005-08-18 |
US20100056982A1 (en) | 2010-03-04 |
EP1720576A4 (en) | 2010-12-22 |
CA2554591A1 (en) | 2005-08-18 |
CA2457214A1 (en) | 2005-08-06 |
EP2659909A2 (en) | 2013-11-06 |
EP2659909A3 (en) | 2014-08-13 |
EP2494989A1 (en) | 2012-09-05 |
CA2554591C (en) | 2014-12-02 |
CA2470403A1 (en) | 2005-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2554591C (en) | Photodynamic therapy for the treatment of acne | |
EP1755676B1 (en) | Photodynamic therapy for the treatment of hyperactive sebaceous gland disorders using topically applied verteporfin and/or lemuteporfin | |
DK2120921T3 (en) | The use of aminolevulinic acid, and derivatives thereof | |
US20080056996A1 (en) | Photodynamic therapy for the treatment of hair loss | |
US20050090481A1 (en) | Compositions comprising a photosensitizer and a skin-penetration enhancer and their use in photodynamic treatment | |
US20190209686A1 (en) | Pulse photodynamic treatment of acne | |
AU2002340659A1 (en) | Photodynamic therapy for the treatment of hair loss | |
WO2008052350A1 (en) | Photodynamic therapy for the treatment of hidradenitis suppurativa | |
Monfrecola et al. | A critical reappraisal of off-label use of photodynamic therapy for the treatment of non-neoplastic skin conditions | |
Stapleton et al. | Photosensitizers for photodynamic therapy of cutaneous disease | |
JP2006514567A (ja) | 発毛 | |
WO2009093144A2 (en) | Photodynamic therapy of sebaceous gland disorders | |
Ma et al. | Effect of photodynamic therapy using 5-aminolevulinic acid on 4-nitroquinoline-1-oxide-induced premalignant and malignant lesions of mouse tongue | |
AU2011256899B2 (en) | Photodynamic therapy for the treatment of acne | |
AU2011253786B2 (en) | Photodynamic therapy for the treatment of hyperactive sebaceous gland disorders using topically applied hydrophobic green porphyrins | |
MXPA06008949A (en) | Photodynamic therapy for the treatment of acne | |
ZA200606380B (en) | Photodynamic therapy for the treatment of acne vulgaris using topically administered hydrophobic green porphyrins | |
Moy et al. | Photodynamic Therapy for Photodamage, Actinic Keratosis, Cosmetic Practice and Acne in the |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080204 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080204 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101018 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110105 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110113 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110214 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110221 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110314 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110322 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110415 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111121 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120208 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120215 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120315 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120323 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120417 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120424 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120724 |